城建發展(600266.SH):以26.3億元競得北京市豐台區相關項目
格隆匯2月17日丨城建發展(600266.SH)公佈,2022年2月16日公司收到《北京市國有建設用地使用權掛牌出讓成交確認書》(京土儲掛函(豐)[2022]003號),公司的全資子公司北京城建興華地產有限公司以26.3億元的價格競得北京市豐台區盧溝橋街道大井新村三期土地一級開發2502-0030、2505-0031地塊F81綠隔產業用地、R2二類居住用地(配建“保障性租賃住房”)國有建設用地使用權。
項目位於西四環外盧溝橋街道,青塔商圈南側,建設用地面積4.72萬㎡,規劃建築面積11.95萬㎡。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.